Following a full submission
miconazole muco-adhesive buccal tablets (Loramyc) are not recommended for use within NHS Scotland for the treatment of oropharyngeal candidiasis in immunocompromised patients.
Miconazole muco-adhesive buccal tablets were shown to be non-inferior to another locally-acting miconazole preparation in the treatment of oropharyngeal candidiasis in patients with cancer of the head and neck who had received radiotherapy.
There are no data comparing miconazole buccal tablets to treatments currently used in practice in NHS Scotland.
The manufacturer did not present a sufficiently robust analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice79KB (PDF)
- Medicine name:
- miconazole muco adhesive buccal tablet (Loramyc)
- SMC ID:
- Oropharyngeal candidiasis (OPC) in immunocompromised patients
- Pharmaceutical company
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Not recommended
- Date advice published
- 08 December 2008